Moderna's Market Reaction: Understanding the Sell-the-News Phenomenon After Positive Trial Results
Despite positive trial results, Moderna's stock dropped 7.32%, highlighting the sell-the-news trend in biotech.
McKesson's $2.25 Billion Precision Medicine Acquisition: What It Means for Investors
McKesson's $2.25 billion acquisition of Precision Medicine Group signals a strategic move in oncology and life sciences.
Merck and Moderna's mRNA Cancer Vaccine Shows Promise in Phase 3 Trials
Merck and Moderna's mRNA-based cancer vaccine for melanoma shows strong Phase 3 trial results, signaling a shift in cancer therapy.
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's recent FDA approval for an Alzheimer's blood test signals a pivotal moment in diagnostics, impacting investors and patients alik…
Merck and Moderna's Phase 3 Success: A Milestone in Cancer Vaccination
Merck and Moderna report significant success in their Phase 3 trial, reinforcing the role of KEYTRUDA in oncology.
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's FDA approval for an Alzheimer's blood test could reshape the diagnostics landscape and boost investor sentiment.
TG Therapeutics on the Rise: Exploring the Potential of Takeover Speculation
TG Therapeutics gains traction amid takeover rumors, reflecting broader M&A interest in the pharmaceutical sector.
Moderna's Cancer Vaccine Breakthrough: Implications for Investors and Biotech Traders
The recent Phase 3 trial results for Moderna's cancer vaccine have sent shockwaves through the biotech sector, raising investor sentiment dr…
Capricor Therapeutics Faces PDUFA Date: What Investors Should Know
Capricor's stock dropped nearly 8% as it awaits an FDA decision on Deramiocel for Duchenne muscular dystrophy.
Moderna's Cancer Vaccine Triumph: What This Means for Investors
Moderna's stock surged 176.97% after successful Phase 3 trial results for its cancer vaccine, signaling potential market shifts.
Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger
Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million private placement, focusing on oncology.
TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz
TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by its drug BRIUMVI's FDA approval.











